Transactions & Cases Detail



Transaction/Case Details

DiagnoCure announces closing of the PCA3 Asset Sale transaction and special distribution to its shareholders

DATE CLOSED

February 26, 2016

BUSINESS SECTOR

Pharmaceutical / Bio Life Sciences

LEAD OFFICE

Quebec


OVERVIEW

On February 17, 2016, DiagnoCure Inc.  announced  the closing of the previously announced sale of all assets related to DiagnoCure’s PCA3 prostate cancer biomarker to Hologic, Inc. via its wholly-owned subsidiary, Gen-Probe Incorporated (the “PCA3 Asset Sale”). In connection with the PCA3 Asset Sale, the Corporation has repurchased the 4,900,000 series A convertible preferred shares of DiagnoCure held by Gen-Probe Incorporated. DiagnoCure also announced today a return of capital distribution of C$0.1208 per share to its shareholders of record as at the close of business on February 26, 2016 in accordance with the policies of the Toronto Stock Exchange  concerning the process and timeline.

McCarthy Tétrault LLP advised DiagnoCure with a team led by Philippe Leclerc.

Contact


 
For general information on McCarthy Tétrault Transactions & Cases, please contact [email protected].

Related Area of Expertise


Capital Markets
read /

Life Sciences
read /

Pharmaceutical
read /